Prospective Comparison of Surgery Alone and Chemoradiotherapy With Selective Surgery in Resectable Squamous Cell Carcinoma of the Esophagus

Ariga, Hiroyoshi; Nemoto, Kenji; Miyazaki, Shukichi; Yoshioka, Takashi; Ogawa, Yoshiko; Sakayauchi, Toru; Jingu, Keiichi; Miyata, Go; Onodera, Ko; Ichikawa, Hirofumi; Kamei, Takashi; Kato, Shunsuke; Ishioka, Chikashi; Satoh, Susumu; Yamada, Satoshi

doi:10.1016/j.ijrobp.2009.02.086

Cited by 99 publications

(72 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Because of the success of concurrent CRT for unresectable esophageal cancer, definitive CRT has been applied for resectable esophageal cancer (T1-3N0,1M0) since the late 1990s in Japan. Although no randomized clinical trials comparing definitive CRT and surgery for resectable esophageal cancer have been reported, clinical results of concurrent CRT for resectable esophageal cancer are very promising [8][9][10].…”

Section: Introductionmentioning

confidence: 99%

Clinical practice and outcome of radiotherapy for esophageal cancer between 1999 and 2003: the Japanese Radiation Oncology Study Group (JROSG) Survey

et al. 2011

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Clinical practice and outcome of radiotherapy for esophageal cancer between 1999 and 2003: the Japanese Radiation Oncology Study Group (JROSG) Survey

et al. 2011

Self Cite

View full text Add to dashboard Cite

show abstract

“…51,52) To date, there are nine observational studies comparing dCRT with surgery. [53][54][55][56][57][58][59][60][61] Of them, five reports were submitted from Japan and in two out of nine studies, surgery was shown to significantly extend the overall survival. Consequently, dCRT has been used as an alternative to surgery in patients unable to undergo surgical treatment.…”

Section: Definitive Chemoradiotherapymentioning

confidence: 99%

Current Advancement in Multidisciplinary Treatment for Resectable cStage II/III Esophageal Squamous Cell Carcinoma in Japan

Matsuda

Takeuchi

Kawakubo

et al. 2016

ATCS

View full text Add to dashboard Cite

Multidisciplinary treatment comprising surgery, chemotherapy, and radiotherapy for resectable esophageal squamous cell carcinoma (ESCC) is widely used with improved prognosis. Transthoracic esophagectomy (TTE) with extended lymph node (LN) dissection, known as three field LN dissection, has been recommended for ESCC using open thoracotomy or the thoracoscopic approach. The Japan Clinical Oncology Group (JCOG) trial (JCOG1409) is investigating the patients' long term survival using the thoracoscopic approach that has been shown to reduce the incidence of postoperative respiratory complication. For perioperative treatment, neoadjuvant chemotherapy using cisplatin plus 5-fluorouracil (5-FU), has been accepted as the standard of care in Japan based on the JCOG9907 trial. In Western countries, neoadjuvant chemoradiotherapy was shown to prolong overall survival for esophageal cancer, including ESCC. Although surgery has been recognized as an initial curative treatment for esophageal cancer, definitive chemoradiotherapy is an alternative treatment for patients who are unable to undergo thoracotomy or who decline to undergo surgery. This article reviews multidisciplinary treatment advances for ESCC. However, current standard treatments are country dependent and the ongoing trial may help standardize ESCC treatment across various societies.

show abstract

“…11,[25][26][27][28][29][30][31][32][33][34][35][36] Among the 12 randomized trials, preoperative CRT improves the OS rate of patients with esophageal cancer in only five trials. 11,29,30,33,35 Despite some studies not showing the survival benefit, the advantages of preoperative CRT could be illustrated in certain aspects, such as improved local control rate 25,29 and better complete resection rate. 25,28,30 The Irish trial 33 was a small randomized trial in 113 patients with AC randomized to surgery alone vs preoperative CRT with two cycles of cisplatin/fluorouracil and 40 Gy in 15 fractions.…”

Section: Multimodal Therapy For Esophageal Cancermentioning

confidence: 99%

“…38 Neoadjuvant CRT also reduces the risk of distant recurrence. 35 The meta-analysis of randomized trials comparing neoadjuvant CRT and surgery alone for esophageal cancer also demonstrated that preoperative CRT could improve the survival and local control. 39 The meta-analysis by Sjoquist et al 40 included 12 trials that were randomized comparisons …”

Section: Multimodal Therapy For Esophageal Cancermentioning

confidence: 99%

Esophageal cancer: comparative effectiveness of treatment options

Cai¹,

Lin²

2016

CER

View full text Add to dashboard Cite

Esophageal cancer is a lethal disease. Multimodal therapy has improved the survival and local control for locally advanced esophageal cancer compared to surgery alone. Neoadjuvant chemoradiotherapy (CRT) plus surgery is the accepted standard of care for operable esophageal cancer. Pathologic complete response is very common, ranging from 18% to 43%, and it is an independent favorable prognostic factor for survival. Salvage surgery after definitive CRT may be safe and feasible for patients with esophageal cancer who achieve pathologic complete response after neoadjuvant CRT. For inoperable cases, definitive CRT is an alternative treatment modality. Intensity-modulated radiation therapy may reduce treatment-related toxicities due to its better dose homogeneity and conformity compared to three-dimensional conformal radiotherapy. Proton therapy can further improve target conformity and normal tissue sparing when compared to photon therapy (three-dimensional conformal radiotherapy and intensitymodulated radiation therapy) and, therefore, likely to further improve the treatment outcomes of patients. This article compares the effectiveness of the various treatment approaches in the definitive or neoadjuvant setting and reviews the evidence on the benefit of utilizing advanced radiation techniques for the curative management of esophageal cancer.

show abstract

Prospective Comparison of Surgery Alone and Chemoradiotherapy With Selective Surgery in Resectable Squamous Cell Carcinoma of the Esophagus

Cited by 99 publications

References 19 publications

Clinical practice and outcome of radiotherapy for esophageal cancer between 1999 and 2003: the Japanese Radiation Oncology Study Group (JROSG) Survey

Clinical practice and outcome of radiotherapy for esophageal cancer between 1999 and 2003: the Japanese Radiation Oncology Study Group (JROSG) Survey

Current Advancement in Multidisciplinary Treatment for Resectable cStage II/III Esophageal Squamous Cell Carcinoma in Japan

Esophageal cancer: comparative effectiveness of treatment options

Contact Info

Product

Resources

About